Alemtuzumab (Campath-1H)
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-cell Lymphomas
Conditions
Peripheral T-cell Lymphomas
Trial Timeline
Sep 1, 2006 → May 1, 2015
NCT ID
NCT00453427About Alemtuzumab (Campath-1H)
Alemtuzumab (Campath-1H) is a phase 1/2 stage product being developed by Sanofi for Peripheral T-cell Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT00453427. Target conditions include Peripheral T-cell Lymphomas.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00453427 | Phase 1/2 | Completed |
Competing Products
20 competing products in Peripheral T-cell Lymphomas